Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, first-line study of tesevatinib monotherapy in patients with EGFR-mutant non-small cell lung cancer who present with CNS metastases

Next Previous
X
Search
Trial Profile

A randomized, first-line study of tesevatinib monotherapy in patients with EGFR-mutant non-small cell lung cancer who present with CNS metastases

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tesevatinib (Primary)
  • Indications Brain metastases; Meningeal carcinomatosis; Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 22 Mar 2017 According to a Kadmon Corporation media release, the company expects to initiate this trial in the second quarter of 2017.
    • 13 Dec 2016 New trial record
    • 06 Dec 2016 According to a Kadmon media release, based on the interim results of another trial (see profile 264084) company is planning to initiate this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top